{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
M006
(2023)
Source URL:
First approved in 2023
Source:
M006
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2023)
Source URL:
First approved in 2023
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M006
(2023)
Source URL:
First approved in 2023
Source:
M006
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
weight loss gummies by XIAN CHIANG COMPANY LIMITED
(2023)
Source URL:
First approved in 2023
Source:
weight loss gummies by XIAN CHIANG COMPANY LIMITED
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M020
(2023)
Source URL:
First approved in 2023
Source:
M020
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 358B
(2023)
Source URL:
First approved in 2023
Source:
21 CFR 358B
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA125738
(2023)
Source URL:
First approved in 2023
Source:
BLA125738
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Tiger Pain by ZHENGZHOU GIANT BIOCHEMISTRY GROUP CO.,LTD
(2023)
Source URL:
First approved in 2023
Source:
Tiger Pain by ZHENGZHOU GIANT BIOCHEMISTRY GROUP CO.,LTD
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M020
(2023)
Source URL:
First approved in 2023
Source:
M020
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Obstetrix EC by Seyer Pharmatec, Inc.
(2023)
Source URL:
First approved in 2023
Source:
Obstetrix EC by Seyer Pharmatec, Inc.
Source URL:
Class:
STRUCTURALLY DIVERSE